---
$id: https://graph.org.ai/products/commodity/51202302
$type: Product
source: UNSPSC
code: "51202302"
title: "Briakinumab"
class: "51202300"
classTitle: "Immunosupressant amino acids"
family: "51200000"
familyTitle: "Immunomodulating drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Briakinumab

**UNSPSC Code**: 51202302
**Class**: [Immunosupressant amino acids](Immunosupressant amino acids.mdx)
**Family**: [Immunomodulating drugs](../Immunomodulating drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a monoclonal antibody with the molecular formula C6376H9874N1722O1992S44, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 978I8M0P8X, more generally known as briakinumab. European Medicines Agency schedules briakinumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31454. The term BRIAKINUMAB is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 24, No. 1, 2010 list 63. As of Q4 2014, BRIAKINUMAB remains US FDA's Preferred Term for this commodity.

